Xtant Medical Holdings has announced the commercial launch of OsteoFactor Pro™, an allogeneic growth factor solution designed to improve bone healing and surgical outcomes in orthopedic and spine procedures.

OsteoFactor Pro™ is described as a naturally derived formulation rich in growth factors, intended to enhance the biological activity and regenerative potential when combined with orthobiologic scaffolds. It has a biphasic release profile characterized by an initial bolus followed by sustained release, aiming to stimulate key bone regeneration processes, including angiogenesis (formation of new blood vessels), chemotaxis (cell migration), and osteogenesis (bone formation).

The product is designed as an off-the-shelf, ready-to-use solution compatible with a variety of scaffolds, including synthetic, allograft, and autograft materials, providing surgeons with versatility in different bone regeneration strategies.

OsteoFactor Pro™ is now available through Xtant Medical’s nationwide distribution network.

Mark Schallenberger, COO of Xtant Medical added, “With the launch of OsteoFactor Pro™, Xtant becomes the first vertically integrated company to offer solutions across all five major orthobiologic categories—demineralized bone matrix, cellular allografts, synthetics, structural allografts, and now growth factors. This milestone reflects our long-term commitment to innovation, scalability, and meeting the full spectrum of surgeon and patient needs in regenerative medicine.”